

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Ruben et al.

Application Number: to be assigned

Group Art Unit: to be assigned

Filed: herewith

Examiner: to be assigned

Title: 186 Human Secreted Proteins

Attny. Docket No. PZ002P2C1

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir :

Prior to the prosecution of the above-captioned application, please enter the following amendments.

***Amendments***

**In the Specification**

Please replace the first paragraph on page 1 with the following rewritten paragraph:

-- This application is a continuation application of U.S. Application No. 09/809,391, filed March 16, 2001, which application claims benefit under 35 U.S.C. § 119(e) from U.S. Provisional Patent Application Serial No. 60/190,068 filed March 17, 2000, which is hereby incorporated by reference; and which application is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of copending United States patent application Serial No. 09/149,476, filed September 8, 1998, which is hereby incorporated by reference, and which is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of International Application No. PCT/US98/04493, filed March 6, 1998 (published in English), which is hereby incorporated by reference, which claims benefit under 35 U.S.C. § 119(e) based on the following U.S. Provisional Applications, all of which are hereby incorporated by reference: --

## **In the Claims**

Please amend the claim 17 as follows:

17. (Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

Please add the following claim:

-- 24. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1. --

0988217.061801  
"08T90" 1728860

## REMARKS

The specification has been amended to add priority information. The claims have been amended to more particularly point out and distinctly claim the subject matter applicants regard as the invention. Support for new claim 24 can be found throughout the application as filed. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

No new matter has been introduced.

Applicants believe that no fee is required for this submission. However, should a fee be due, please charge such fee to Deposit Account No. 08-3425.

Respectfully submitted

Date: June 18, 2001

  
Kenley K. Hoover (Reg. No. 40,302)  
Attorney for Applicants

Human Genome Sciences, Inc.  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 610-5771 (telephone)

KKH/SA/ur

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Ruben et al.

Application Number: to be assigned

Group Art Unit: to be assigned

Filed: herewith

Examiner: to be assigned

Title: 186 Human Secreted Proteins

Attny. Docket No. PZ002P2C1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

**In the Specification**

On page 1, the first paragraph has been changed as follows:

This application is a continuation application of U.S. Application No. 09/809,391, filed March 16, 2001, which [This] application claims benefit under 35 U.S.C. § 119(e) from U.S. Provisional Patent Application Serial No. 60/190,068 filed March 17, 2000, which is hereby incorporated by reference; and which [this] application is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of copending United States patent application Serial No. 09/149,476, filed September 8, 1998, which is hereby incorporated by reference, and which is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of [copending] International Application No. PCT/US98/04493, filed March 6, 1998 (published in English), which is hereby incorporated by reference, which claims benefit under 35 U.S.C. § 119(e) based on the following U.S. Provisional Applications, all of which are hereby incorporated by reference: --

**In the Claims:**

Claim 17 has been amended as follows:

17. (Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 [or the polynucleotide of claim 1].